schliessen

Filtern

 

Bibliotheken

The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma.

The treatment landscape for renal cell carcinoma (RCC) is a dynamic process that has seen considerable change in recent years. We have seen a rebirth of original breakthroughs with immune checkpoint inhibitors showing promise in patients with treatment-refractory disease. The optimal sequencing of t... Full description

Journal Title: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2016, Vol.35, pp.113-117
Main Author: Hutson, Thomas E
Other Authors: Thoreson, Gregory R , Figlin, Robert A , Rini, Brian I
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1548-8756 ; DOI: 10.14694/EDBK_158892
Link: http://search.proquest.com/docview/1793911394/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest1793911394
title: The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma.
format: Article
creator:
  • Hutson, Thomas E
  • Thoreson, Gregory R
  • Figlin, Robert A
  • Rini, Brian I
subjects:
  • Anilides–Therapeutic Use
  • Carcinoma, Renal Cell–Drug Therapy
  • Cell Cycle Checkpoints–Genetics
  • Disease-Free Survival–Immunology
  • Humans–Pathology
  • Interleukin-2–Drug Effects
  • Molecular Targeted Therapy–Immunology
  • Neoplasm Metastasis–Genetics
  • Phenylurea Compounds–Therapeutic Use
  • Protein Kinase Inhibitors–Therapeutic Use
  • Pyridines–Therapeutic Use
  • Quinolines–Therapeutic Use
  • Receptors, Vascular Endothelial Growth Factor–Therapeutic Use
  • Tor Serine-Threonine Kinases–Antagonists & Inhibitors
  • Vascular Endothelial Growth Factor A–Genetics
  • Vascular Endothelial Growth Factor A–Antagonists & Inhibitors
  • Vascular Endothelial Growth Factor A–Genetics
  • Vascular Endothelial Growth Factor A
ispartof: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2016, Vol.35, pp.113-117
description: The treatment landscape for renal cell carcinoma (RCC) is a dynamic process that has seen considerable change in recent years. We have seen a rebirth of original breakthroughs with immune checkpoint inhibitors showing promise in patients with treatment-refractory disease. The optimal sequencing of treatments and incorporation of novel therapeutics are actively being investigated and have yet to be determined. The clinical challenges of this evolving treatment paradigm can be attributed to cost considerations, toxicity, and defining endpoints in the management of advanced RCC. As novel therapeutics emerge, finding the optimal treatment regimen for patients will have an increasing focus on patient-centered outcomes and improvement in quality of life in addition to improving survival.
language: eng
source:
identifier: E-ISSN: 1548-8756 ; DOI: 10.14694/EDBK_158892
fulltext: no_fulltext
issn:
  • 15488756
  • 1548-8756
url: Link


@attributes
ID1767776587
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid1793911394
sourceidproquest
recordidTN_proquest1793911394
sourcesystemPC
pqid1793911394
display
typearticle
titleThe Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma.
creatorHutson, Thomas E ; Thoreson, Gregory R ; Figlin, Robert A ; Rini, Brian I
contributorHutson, Thomas E (correspondence author) ; Hutson, Thomas E (record owner)
ispartofAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2016, Vol.35, pp.113-117
identifierE-ISSN: 1548-8756 ; DOI: 10.14694/EDBK_158892
subjectAnilides–Therapeutic Use ; Carcinoma, Renal Cell–Drug Therapy ; Cell Cycle Checkpoints–Genetics ; Disease-Free Survival–Immunology ; Humans–Pathology ; Interleukin-2–Drug Effects ; Molecular Targeted Therapy–Immunology ; Neoplasm Metastasis–Genetics ; Phenylurea Compounds–Therapeutic Use ; Protein Kinase Inhibitors–Therapeutic Use ; Pyridines–Therapeutic Use ; Quinolines–Therapeutic Use ; Receptors, Vascular Endothelial Growth Factor–Therapeutic Use ; Tor Serine-Threonine Kinases–Antagonists & Inhibitors ; Vascular Endothelial Growth Factor A–Genetics ; Vascular Endothelial Growth Factor A–Antagonists & Inhibitors ; Vascular Endothelial Growth Factor A–Genetics ; Vascular Endothelial Growth Factor A
languageeng
source
descriptionThe treatment landscape for renal cell carcinoma (RCC) is a dynamic process that has seen considerable change in recent years. We have seen a rebirth of original breakthroughs with immune checkpoint inhibitors showing promise in patients with treatment-refractory disease. The optimal sequencing of treatments and incorporation of novel therapeutics are actively being investigated and have yet to be determined. The clinical challenges of this evolving treatment paradigm can be attributed to cost considerations, toxicity, and defining endpoints in the management of advanced RCC. As novel therapeutics emerge, finding the optimal treatment regimen for patients will have an increasing focus on patient-centered outcomes and improvement in quality of life in addition to improving survival.
version3
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/1793911394/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Hutson, Thomas E
1Thoreson, Gregory R
2Figlin, Robert A
3Rini, Brian I
titleThe Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma.
subject
0Anilides–Therapeutic Use
1Carcinoma, Renal Cell–Drug Therapy
2Cell Cycle Checkpoints–Genetics
3Disease-Free Survival–Immunology
4Humans–Pathology
5Interleukin-2–Drug Effects
6Molecular Targeted Therapy–Immunology
7Neoplasm Metastasis–Genetics
8Phenylurea Compounds–Therapeutic Use
9Protein Kinase Inhibitors–Therapeutic Use
10Pyridines–Therapeutic Use
11Quinolines–Therapeutic Use
12Receptors, Vascular Endothelial Growth Factor–Therapeutic Use
13Tor Serine-Threonine Kinases–Antagonists & Inhibitors
14Vascular Endothelial Growth Factor A–Genetics
15Vascular Endothelial Growth Factor A–Antagonists & Inhibitors
16Vascular Endothelial Growth Factor A
general
0English
110.14694/EDBK_158892
2MEDLINE (ProQuest)
3ProQuest Biological Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
11Biological Science Index (ProQuest)
sourceidproquest
recordidproquest1793911394
issn
015488756
11548-8756
rsrctypearticle
creationdate2016
addtitleAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
searchscope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
scope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
lsr43
01007527false
11007944false
21009130false
310000004false
410000038false
510000050false
610000120false
710000159false
810000238false
910000253false
1010000260false
1110000270false
1210000271false
1310000302false
1410000350false
contributorHutson, Thomas E
startdate20160101
enddate20160101
citationpf 113 pt 117 vol 35
lsr30VSR-Enriched:[description, date, pqid, issn]
sort
titleThe Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma.
authorHutson, Thomas E ; Thoreson, Gregory R ; Figlin, Robert A ; Rini, Brian I
creationdate20160101
lso0120160101
facets
frbrgroupid8364949171721973035
frbrtype5
newrecords20181218
languageeng
creationdate2016
topic
0Anilides–Therapeutic Use
1Carcinoma, Renal Cell–Drug Therapy
2Cell Cycle Checkpoints–Genetics
3Disease-Free Survival–Immunology
4Humans–Pathology
5Interleukin-2–Drug Effects
6Molecular Targeted Therapy–Immunology
7Neoplasm Metastasis–Genetics
8Phenylurea Compounds–Therapeutic Use
9Protein Kinase Inhibitors–Therapeutic Use
10Pyridines–Therapeutic Use
11Quinolines–Therapeutic Use
12Receptors, Vascular Endothelial Growth Factor–Therapeutic Use
13Tor Serine-Threonine Kinases–Antagonists & Inhibitors
14Vascular Endothelial Growth Factor A–Genetics
15Vascular Endothelial Growth Factor A–Antagonists & Inhibitors
16Vascular Endothelial Growth Factor A
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
9Biological Science Index (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontrib
0Hutson, Thomas E
1Thoreson, Gregory R
2Figlin, Robert A
3Rini, Brian I
jtitleAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
aulast
0Hutson
1Thoreson
2Figlin
3Rini
aufirst
0Thomas E
1Gregory R
2Robert A
3Brian I
au
0Hutson, Thomas E
1Thoreson, Gregory R
2Figlin, Robert A
3Rini, Brian I
addauHutson, Thomas E
atitleThe Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma.
jtitleAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
date2016
risdate20160101
volume35
spage113
epage117
pages113-117
eissn1548-8756
formatjournal
genrearticle
ristypeJOUR
doi10.14694/EDBK_158892
urlhttp://search.proquest.com/docview/1793911394/
issn15488748